Adebrelimab plus temozolomide with or without hyperbaric oxygen for glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination for people with newly diagnosed glioblastoma, a type of brain cancer. It adds an immunotherapy drug (adebrelimab) to standard chemotherapy, and some participants also receive hyperbaric oxygen therapy, which may help the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with glioblastoma and have completed standard radiation and chemotherapy (temozolomide).
- You are able to care for yourself (Karnofsky score of 70 or higher).
- You are not taking more than 4 mg of dexamethasone (a steroid) per day.
- You have adequate organ function (bone marrow, liver, and blood clotting).
- You have not had prior immunotherapy or certain other brain tumor treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—vebreltinib and temozolomide—for people with a type of brain cancer called glioblastoma. It is for those who have already had surgery to remove as much of the tumor as possible.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.